Skip to main content

Table 2 Clinical characteristics of patients at baseline

From: Clinical and immunological outcomes according to adherence to first-line HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa

Variable All patients (N = 625)
Median CD4+ T cell count at baseline (cells/μl)  
cells/μl [median (IQR)] 149 (114)
[calculated on 593/625 pts]
CD4 T cell count at baseline  
 -< 50 cells/μl 88/593 (14.8)
 -> 50 cells/μl 505/593 (85.2)
HIV-type infection  
 -HIV-1 587/625 (93.9)
 -HIV-2 10/625 (1.6)
 -HIV-1 + HIV-2 28/625 (4.5)
WHO clinical stage at baseline  
 -Early (stage 1 and 2) 309/625 (49.4)
 -Advanced (3 and 4) 316/625 (50.6)
HAART regimen  
 -2NRTIs + 1NNRTI 549/625 (87.8)
 -2NRTIs + 1PI/r 76/625 (12.2)
HAART regimen including FDC  
 -Yes 474/625 (75.8)
 -No 151/625 (24.2)
  1. Notes: IQR: Interquartile range; HAART: highly active antiretroviral therapy; NRTIs: nucleoside reverse transcriptase inhibitors; NNRTIs: non nucleoside reverse transcriptase inhibitors; PI/r: protease inhibitors boostered by ritonavir; FDC: fixed dose combination; All values are expressed as N (%).